Russell Investments Group, Ltd. Magenta Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$2.55 - $5.23 $5,477 - $11,234	-2,148 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$6.07 - $9.89 $25,135 - $40,954	-4,141 Reduced 65.85%	2,148 $15,000
Q2 2021 Aug 04, 2021	SELL	$9.76 - $14.15 $280,600 - $406,812	-28,750 Reduced 82.05%	6,289 $60,000
Q1 2021 May 10, 2021	SELL	$7.66 - $13.38 $333,370 - $582,310	-43,521 Reduced 55.4%	35,039 $414,000
Q4 2020 Feb 08, 2021	SELL	$6.1 - $7.94 $68,295 - $88,896	-11,196 Reduced 12.47%	78,560 $614,000
Q3 2020 Nov 09, 2020	BUY	$6.52 - $8.94 $297,527 - $407,959	45,633 Added 103.42%	89,756 $608,000
Q2 2020 Aug 05, 2020	BUY	$6.18 - $10.76 $8,380 - $14,590	1,356 Added 3.17%	44,123 $330,000
Q1 2020 May 06, 2020	BUY	$6.03 - $15.24 $145,316 - $367,268	24,099 Added 129.09%	42,767 $270,000
Q4 2019 Jan 29, 2020	SELL	$9.07 - $15.84 $389,765 - $680,692	-42,973 Reduced 69.71%	18,668 $282,000
Q3 2019 Nov 01, 2019	BUY	$9.63 - $14.0 $593,602 - $862,974	61,641 New	61,641 $631,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.